GSK
Last updated Jun 17, 2026
Evidence Sources
9
Competitive Findings
1
Portfolio Developments
2
Regulatory Precedents
8
Clinical Programs
1
Confidence Coverage
71%
Audit
- Competitor findings: 1
- Portfolio developments: 2
- Self-competition findings removed: 2
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Infectious Disease
- Antifungal
- Neurology
- Smoking Cessation
- Oncology
Highest priority development: Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Portfolio development
Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3 is an owned GSK portfolio development in Infectious Disease · Pneumococcal Vaccine.
Competitive pressure: High
Portfolio impact: High
Evidence coverage: 71%
Active Signals
20
Investigate Priority
1
Opportunity Score
2035
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 17, 2026Score 110OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients
Infectious Disease · COVID-19
- MonitorJun 17, 2026Score 109Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough
Respiratory · Chronic Cough
- MonitorJun 18, 2026Score 106FDA Accepts Supplement Application for SKYRIZI (Risankizumab) by AbbVie
Immunology · IL-23
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)Humanexa SignalsPfizerPortfolio
- Low Confidence · 0%Sources (3)PubMedPfizerPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
- Janssen (named in signal competitive context)Moderate Confidence · 72%
Elevated competitive pressure
Sources (2)FDACompetitiva
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA Approves First Generics of Gilotrif (afatinib) TabletsHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancerHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — BREXAFEMME (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — BREXAFEMME (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Janssen (named in signal competitive context)Moderate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 106Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Infectious Disease · Pneumococcal Vaccine
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to GSK right now?
- Which regulatory precedents should GSK monitor in Infectious Disease and Antifungal?
- How does Janssen compare to the nearest competitive programs?
- What signals require immediate investigation for GSK?
- Summarize the strategic implications of recent developments for GSK.
- Where is the greatest uncertainty in GSK's competitive positioning?